Drugs / p946
p946
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003224 | Feb 1996 → Aug 2000 | cutaneous melanoma | University of Virginia | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | p946 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003224 ↗ |
| Known as | gp100(280) | “A melanoma vaccine composed of HLA-A2-restricted peptide YLEPGPVTA (gp100(280)), with or without a modified T-helper epitope from tetanus toxoid AQYIKANSKFIGITEL, has been...” PMID 11595689 ↗ Oct 2001 |
| Known as | peptide 946, gp100 [280-288], YLEPGPVTA | “peptide 946, gp100 [280-288], YLEPGPVTA” NCT00003224 ↗ |
| Modality | Vaccine | “This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.” NCT00003224 ↗ |
| Route | Subcutaneous | “Arm I: Patients receive peptide 946 melanoma vaccine (peptide 946) emulsified with QS21 subcutaneously (SQ).” NCT00003224 ↗ |